The WILLOW trial reveals Enpatoran’s strong performance in mucocutaneous lupus, achieving high CLASI-50 and CLASI-70 response rates, remission milestones, and rapid IFN gene suppression in both CLE and SLE patients.
DERMATOLOGYIMMUNOLOGYRHEUMATOLOGY
< class="penci-entry-title entry-title grid-title penci_grid_title">Enpatoran delivers robust skin lupus efficacy across CLE and SLE, achieving high CLASI responses and early IFN suppression in WILLOW trial